Business
AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting
Research Triangle Park, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the company’s manufacturing technologies AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 6 presentations offering insights into the research and development of adeno-associated virus (AAV) therapies for a range of diseases as well
About this update from Bayer Ag
[{"type":"text","content":"Research Triangle Park, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) --","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the company’s manufacturing technologies","length":166,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":166,"olType":false},{"type":"text","content":"AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 6 presentations offering insights into the research and development of adeno-associated virus (AAV) therapies for a range of diseases as well as advancements in manufacturing technologies, at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Meeting taking place October 7–10, 2025, in Seville, Spain.","length":444,"tagName":"p"},{"type":"text","content":""ESGCT brings together leading researchers, clinicians, and industry experts to drive forward the field of gene and cell therapy and, as a company with a significant presence both in U.S. and Europe, this meeting is a special opportunity for us to interact with these prestigious stakeholders,” said Gustavo Pesquin, Chief Executive Officer, AskBio. “This year, alongside Viralgen, AskBio is contributing six presentations that highlight not only our latest clinical milestones but also our advanced manufacturing capabilities. As we share new data spanning discovery, preclinical, and clinical stages, we reaffirm our commitment to delivering therapies at scale, with robust production and translational excellence. It is through this confluence of scientific rigor and operational strength that we aim to translate hope into real-world impact for patients facing serious rare and more common diseases."","length":914,"tagName":"p"},{"type":"text","content":"AskBio’s presentations include (all times CEST):","length":48,"tagName":"p"},{"type":"text","content":"Oral","length":4,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Delivery technologies: A Strategic Platform Roadmap for Commercializing Gene Therapy. Wednesday, October 8, from 6:00-7:30 p.m. (Session 6ª: Manufacturing 1: Delivery technologies, Parallel A). Cesar Trigueros, Viralgen.","length":220,"tagName":"p"}]}],"tagName":"ul",...